Stockholders Clear Blank Check Preferred Stock, Opening Door to 95% Dilution
MEDS sits 20% above its 52-week low of $0.823 on elevated volume (30× avg).
Summary
Stockholders approved a blank check preferred stock authorization that enables conversion of $21.1M in convertible notes into Series A Preferred Stock with a variable conversion price — potentially diluting existing shareholders by up to 95%.
Key Events · Financing and Capital Events · MEDS
-
Blank Check Preferred Stock Authorized
Stockholders holding 50.2% of outstanding shares approved an amendment authorizing 1,000,000 shares of blank check preferred stock via written consent dated August 25, 2026.
-
Series A Preferred Stock Terms Revealed
The Series A Preferred Stock carries a $1,000 stated value, 10% annual dividend accrual after six months, and a conversion price reset to the lesser of $50.00 or market price with a floor dropping to 20% of the closing price on the Mandatory Conversion Date.
-
Up to 95.2% Dilution to Existing Shareholders
Company dilution tables show that at a $0.50 conversion price, existing common stockholders would face approximately 95.2% dilution from conversion of the May 2026 Notes and exercise of PIPE and PA Warrants.
-
Death-Spiral Financing Structure
The variable conversion price means a declining stock price triggers issuance of more shares, which can further depress the stock price and encourage short selling — a toxic feedback loop.
Analysis · MEDS · Trade & Services
A written consent from holders of 50.2% of outstanding shares authorizes 1,000,000 shares of blank check preferred stock, clearing the way for conversion of $21.1M in May 2026 convertible notes into Series A Preferred Stock. The filing reveals the full terms: a $1,000 stated value, 10% dividend accrual after six months, and a conversion price that resets to the lesser of $50.00 or the market price with a floor that drops to 20% of the closing price on the Mandatory Conversion Date. The company's own dilution tables show existing common stockholders could face up to 95.2% dilution at a $0.50 conversion price. This is a toxic financing structure — the lower the stock price falls, the more shares get issued, creating a death-spiral dynamic that could crush the stock. The filing also confirms the election of five directors and ratification of Suri & Co. as auditor, but the preferred stock authorization is the dominant event.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MEDS was trading at $0.99 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $0.82 to $86.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.